AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis

Second AVROBIO gene therapy program that has been granted rare pediatric disease designation by FDA AVR-RD-04 has previously received orphan drug designation from FDA and EMA AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy compa